The fight to keep Tavneos (avacopan) on the market is continuing, with Amgen Inc. submitting its defense of the vasculitis drug to the U.S. FDA just as the July 29 deadline approached. The submission is in support of a request for a hearing on Tavneos after the FDA proposed on April 30 that the marketing approval be annulled.